Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P01579

UPID:
IFNG_HUMAN

ALTERNATIVE NAMES:
Immune interferon

ALTERNATIVE UPACC:
P01579; B5BU88; Q53ZV4

BACKGROUND:
The protein Interferon gamma stands at the forefront of immune defense, orchestrating a complex network of responses against pathogens and tumors. By interacting with its receptor IFNGR1, it triggers a cascade of events leading to the activation of STAT1 and the transcription of genes critical for immune function. Its ability to modify the proteasome and MHC complexes underscores its importance in antigen processing and presentation.

THERAPEUTIC SIGNIFICANCE:
Given its central role in immune responses, Interferon gamma is a key target in the treatment of Aplastic anemia and Immunodeficiency 69. Its capacity to regulate immune cell activation and influence antigen presentation pathways offers a promising avenue for therapeutic intervention. The exploration of Interferon gamma's functions could pave the way for breakthroughs in managing these immune-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.